Modalis Therapeutics Unveils Groundbreaking Gene Therapy
Company Announcements

Modalis Therapeutics Unveils Groundbreaking Gene Therapy

Modalis Therapeutics Corporation (JP:4883) has released an update.

Modalis Therapeutics Corporation is set to present their cutting-edge CRISPR-GNDM® technology and share data supporting the development of their lead program MDL-101 for LAMA2-Congenital Muscular Dystrophy at the 5th Annual Genome Editing Therapeutics Summit. The company’s innovative epigenome editing approach offers potential for a one-time, durable treatment for this rare genetic disease. Modalis Therapeutics, a leader in the field of genome editing therapeutics, continues to advance its research with a focus on non-hepatic disorders.

For further insights into JP:4883 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App